Trial Profile
An Open-label, Randomised, Single Dose, Parallel-group Phase I Study to Investigate the Pharmacokinetic Properties of 200 mg Nevirapine Extended Release Tablets When Administered Orally as 2x100 mg Tablets or as 4x50 mg Tablets in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jul 2014
Price :
$35
*
At a glance
- Drugs Nevirapine (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 22 Jul 2014 New trial record